Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Short Interest Up 113.1% in March

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 745,300 shares, an increase of 113.1% from the February 28th total of 349,800 shares. Approximately 7.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 7,170,000 shares, the days-to-cover ratio is currently 0.1 days.

Petros Pharmaceuticals Price Performance

Petros Pharmaceuticals stock traded down $0.03 during midday trading on Friday, reaching $0.09. 19,121,165 shares of the company were exchanged, compared to its average volume of 9,052,678. The firm’s 50-day simple moving average is $0.18 and its 200-day simple moving average is $0.28. Petros Pharmaceuticals has a 1 year low of $0.05 and a 1 year high of $1.48. The company has a market capitalization of $973,434.00, a price-to-earnings ratio of -0.02 and a beta of 2.04. The company has a debt-to-equity ratio of 1.58, a quick ratio of 0.74 and a current ratio of 0.85.

Petros Pharmaceuticals Company Profile

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).